275 related articles for article (PubMed ID: 16791898)
1. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
Brummel R; Roberts TL; Stacey KJ; Lenert P
Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
[TBL] [Abstract][Full Text] [Related]
2. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
3. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides.
Brummel R; Lenert P
J Immunol; 2005 Feb; 174(4):2429-34. PubMed ID: 15699180
[TBL] [Abstract][Full Text] [Related]
4. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
5. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
[TBL] [Abstract][Full Text] [Related]
6. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
7. B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus.
Goeken JA; Layer T; Fleenor S; Laccheo M; Lenert P
Lupus; 2010 Oct; 19(11):1290-301. PubMed ID: 20605877
[TBL] [Abstract][Full Text] [Related]
8. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
9. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
10. Tonic B cell activation by Radioprotective105/MD-1 promotes disease progression in MRL/lpr mice.
Kobayashi T; Takahashi K; Nagai Y; Shibata T; Otani M; Izui S; Akira S; Gotoh Y; Kiyono H; Miyake K
Int Immunol; 2008 Jul; 20(7):881-91. PubMed ID: 18492657
[TBL] [Abstract][Full Text] [Related]
11. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
Anders HJ; Vielhauer V; Eis V; Linde Y; Kretzler M; Perez de Lema G; Strutz F; Bauer S; Rutz M; Wagner H; Gröne HJ; Schlöndorff D
FASEB J; 2004 Mar; 18(3):534-6. PubMed ID: 14734643
[TBL] [Abstract][Full Text] [Related]
12. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.
Heikenwalder M; Polymenidou M; Junt T; Sigurdson C; Wagner H; Akira S; Zinkernagel R; Aguzzi A
Nat Med; 2004 Feb; 10(2):187-92. PubMed ID: 14745443
[TBL] [Abstract][Full Text] [Related]
13. Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: implications for systemic lupus erythematosus.
Lindau D; Rönnefarth V; Erbacher A; Rammensee HG; Decker P
Eur J Immunol; 2011 Mar; 41(3):669-81. PubMed ID: 21287547
[TBL] [Abstract][Full Text] [Related]
14. [Functional analysis of an autoantigen reactive B cell clone derived from MRL/MP-lpr/lpr mice].
Kobayashi K; Hamano T; Kakishita E
Ryumachi; 1996 Dec; 36(6):844-55. PubMed ID: 9122824
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
16. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
[TBL] [Abstract][Full Text] [Related]
17. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC.
Meyers JA; Mangini AJ; Nagai T; Roff CF; Sehy D; van Seventer GA; van Seventer JM
Cytokine; 2006 Sep; 35(5-6):235-46. PubMed ID: 17052915
[TBL] [Abstract][Full Text] [Related]
18. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
[TBL] [Abstract][Full Text] [Related]
19. CpG DNA stimulates autoreactive immature B cells in the bone marrow.
Azulay-Debby H; Edry E; Melamed D
Eur J Immunol; 2007 Jun; 37(6):1463-75. PubMed ID: 17474151
[TBL] [Abstract][Full Text] [Related]
20. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling.
Rui L; Vinuesa CG; Blasioli J; Goodnow CC
Nat Immunol; 2003 Jun; 4(6):594-600. PubMed ID: 12740574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]